Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02113397 · ClinicalTrials.gov registry record
Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- 1
- Enrollment target
NCT02113397: Clinical Trial study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT02113397 is a clinical trial that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02113397 was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
Primary Outcome
The primary estimate in our study is the mean effects of Continuous Alternating Therapy compared to Cyclic therapy on Simpson Diversity Index (SDI) averaged at month 6
Interventions
- DRUG TOBI™ Podhaler™ 112 mg inhaled twice daily
- DRUG Colistimethate 75 mg inhaled two times daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-08 |
Why NCT02113397 stopped before completion
NCT02113397 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which TOBI™ Podhaler™ 112 mg inhaled twice daily is the first listed.
NCT02113397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02113397 about?
NCT02113397 is a clinical study titled "Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung". The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
What is the current status of trial NCT02113397?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2014-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02113397?
The interventions under investigation include: TOBI™ Podhaler™ 112 mg inhaled twice daily (DRUG), Colistimethate 75 mg inhaled two times daily (DRUG).
Who is sponsoring clinical trial NCT02113397?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia